Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2926118 | Hipertensión | 2007 | 9 Pages |
Abstract
The term metabolic syndrome refers to a group of cardiovascular disease risk factors whose underlying pathophysiology is thought to be related to insulin resistance. This common metabolic disorder is associated to the presence of obesity. A proinflammatory and prothrombotic state probably contributes to the syndrome. The primary consequence of this syndrome is the increased risk for cardiovascular disease and type 2 diabetes. The fundamental approach is weight reduction with dietary measures and increased physical activity. However, drug treatment is also appropriate for specific risk factors. Rimonabant, a selective cannabinoid type 1 receptor blocker, reduces body weight and improves metabolic risk factors in overweight or obese patients and could become the first specific drug treatment for this disorder.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
L. Vigil Medina, M. López Jiménez, R. GarcÃa Carretero,